G. F. Benevolenskaya

Learn More
Sheep polyclonal anti-lipoprotein (a) [anti-Lp(a)] antibodies were used for immunosorbent preparation. The ability of the selective removal of Lp(a) from human plasma by this sorbent was demonstrated in an in vitro study. The material desorbated from the anti-Lp(a) column by acid pH has immunochemical properties identical to those of Lp(a) isolated by(More)
Low density lipoprotein (LDL) (1,03-1,05 g/ml) was utilized as antigen to obtain polyclonal (PcAb) and monoclonal (McAb) antibodies. Immunosorbents capable of selective removing LDL from human plasma were developed on the basis of the antibodies preparation. The sorbents called "Immunoliposorber PcAb" and "Immunoliposorber McAb" are currently undergoing(More)
Lipoprotein (a) Lp (a) of human blood plasma, discovered in 1963 [5], has been the object of the closest attention of biochemists and cardiologists [9, 13, 15]. It has been shown that a high Lp (a) level can be regarded as an independent risk factor of the development of atherosclerosis [4, 9, 10, 13]. In its physicochemical properties Lp (a) resembles a(More)
Sheep polyclonal antibodies to human lipoprotein(a) were used for the development of sandwich enzyme immunoassay. These antibodies virtually do not interact with human plasminogen, apoB-100, or fibrinogen in this assay. The method permits measurements of lipoprotein(a) in a wide range of concentrations: from 2 to 500 mg/dl. The variability of analyses(More)
Three types of sorbents were developed for the specific removal of atherogenic apoB-containing low-density lipoprotein (LDL) and lipoprotein LDL (a) (Lp[a]) from human plasma. Two sorbents contained monospecific sheep polyclonal or mouse monoclonal antibodies against human apoprotein B-100. The third one was intended for specific removal of Lp(a) and(More)
  • 1